VTS-208

N/A

Report date: 2026/06/02 20:00:14

Base Information

Drug NameVTS-208
Drug Alias Nameanti-CD3/anti-CLDN18.2/anti-CDH17 trispecific T-cell engager (VelaVigo)VTS-208
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsClaudin 18 protein modulators +[5] 
TargetsT cell surface glycoprotein CD3Claudin-18 splice variant 2Cadherin-17
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesVelaVigo (Shanghai) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVelaVigo Bio IncVelaVigo (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A